What non‑pharmacologic and pharmacologic treatments are recommended for a patient with generalized anxiety disorder and insomnia who is constantly worried and unable to sleep?

Management of Anxiety and Insomnia

Start with cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, then add pharmacotherapy only if CBT-I alone is unsuccessful. 1

Initial Treatment Approach

First-Line: Cognitive Behavioral Therapy for Insomnia (CBT-I)

• CBT-I should be the initial treatment for all adults with chronic insomnia disorder, including those with comorbid anxiety. 1
• CBT-I combines cognitive therapy, behavioral interventions (sleep restriction and stimulus control), and sleep hygiene education. 1
• This therapy can be delivered through in-person individual or group sessions, telephone/web-based modules, or self-help books by trained clinicians or mental health professionals. 1
• CBT-I provides better overall value than pharmacologic treatment because it is noninvasive with fewer harms, while medications carry risks of serious adverse events. 1

Why CBT-I Works for Both Conditions

• Non-pharmacological sleep interventions produce moderate reductions in anxiety symptoms (effect size = -0.38), with even larger effects in patients with elevated baseline anxiety (effect size = -0.43). 2
• The bidirectional relationship between anxiety and insomnia means treating sleep disturbance can reduce anxiety severity without directly targeting anxiety. 3, 2
• Initiating treatment for insomnia in patients with comorbid GAD and insomnia produces improvements in both sleep quality and anxiety/worry. 4

When to Add Pharmacotherapy

Indications for Medication

• Add pharmacological therapy only after CBT-I alone has been unsuccessful. 1
• The decision should weigh benefits, harms, and costs of short-term medication use. 1

Pharmacologic Options

For Insomnia (FDA-approved agents): 1

• Nonbenzodiazepine hypnotics: zaleplon, zolpidem, eszopiclone
• Benzodiazepines: triazolam, estazolam, temazepam, flurazepam, quazepam
• Orexin receptor antagonist: suvorexant
• Melatonin receptor agonist: ramelteon
• Antidepressant: doxepin

For Generalized Anxiety Disorder: 5, 6

• Selective serotonin reuptake inhibitors (SSRIs)
• Serotonin-norepinephrine reuptake inhibitors (SNRIs)
• Pregabalin
• Benzodiazepines (for short-term use)
• Atypical antipsychotics (e.g., quetiapine) in refractory cases

Critical Safety Warnings

Duration of Pharmacotherapy

• Pharmacologic treatments for insomnia are FDA-approved for short-term use only (4-5 weeks). 1
• Patients should not continue using these drugs for extended periods, as long-term adverse effects are unknown. 1
• If insomnia does not remit within 7-10 days of treatment, further evaluation is required. 1

Serious Adverse Events

• Observational studies link hypnotic drugs to dementia, serious injury, and fractures. 1
• FDA labels warn of daytime impairment, "sleep driving," behavioral abnormalities, and worsening depression. 1
• The FDA recommends lower dosages than those used in many studies, especially for older adults. 1

Clinical Pitfalls to Avoid

• Do not start with medications before attempting CBT-I, as this exposes patients to unnecessary harm without the durable benefits of behavioral therapy. 1
• Do not continue hypnotic medications beyond short-term use, as evidence for long-term safety is insufficient. 1
• Do not overlook the anxiety component—while treating insomnia can reduce anxiety, patients with GAD typically require specific anxiety-focused treatment (SSRIs/SNRIs or CBT for GAD). 5, 6
• Do not assume benzodiazepines are appropriate for long-term anxiety management—they are intended for short-term use and carry dependency risks. 7, 6

Treatment Sequencing for Comorbid GAD and Insomnia

• When both conditions are present, evidence suggests treating GAD first may produce superior benefits in both anxiety and sleep. 4
• However, the American College of Physicians guideline prioritizes CBT-I as first-line regardless of comorbidity, given its effectiveness for both sleep and anxiety symptoms. 1, 2
• Adding insomnia-specific treatment after anxiety treatment leads to additional improvements in worry and sleep quality. 4

Monitoring and Follow-Up

• Assess response to CBT-I after 4-6 weeks. 1
• If pharmacotherapy is added, re-evaluate within 7-10 days and discontinue if ineffective. 1
• Screen for worsening depression, suicidal ideation, and cardiovascular risk, as GAD increases risk for suicide and cardiovascular events. 5
• Monitor for medication adverse effects including falls, cognitive impairment, and behavioral changes. 1